

**AMENDMENTS TO THE CLAIMS**

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the claims**

Claim 1 (Currently Amended): A method of suppressing a respiratory syncytial virus (RSV) infection in an individual who has been exposed to RSV, comprising administering a composition to the respiratory tract of an said individual, said composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said individual, wherein the ISS comprises the sequence 5'-C, G-3', wherein an RSV antigen is not administered in conjunction with administration of said composition, wherein an immunostimulatory cytokine is not administered in conjunction with administration of said composition and wherein said composition is administered in an amount sufficient to suppress an RSV infection.

Claim 2 (Original): The method of claim 1, wherein the ISS comprises the sequence 5'-T, C, G-3'.

Claim 3 (Original): The method of claim 1, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3' or 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3'.

Claim 4 (Original): The method of claim 3, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTCC-3', 5'-AACGTTCG-3', 5'-GACGTTCC-3', and 5'-GACGTTCG-3'.

Claim 5 (Original): The method of claim 1, wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTCGAGATGA-3' (SEQ ID NO:1).

Claim 6 (Original): The method of claim 1, wherein the individual is a mammal.

Claim 7 (Cancelled)

Claim 8 (Previously Amended): The method of claim 1, wherein administration is to a lung.

Claim 9 (Previously Amended): The method of claim 1, wherein administration is to the nasal passages.

Claim 10 (Original): The method of claim 1, wherein the suppression comprises a reduction of RSV titer in a biological sample from said individual.

Claim 11 (Currently Amended): A kit for use in suppressing a respiratory syncytial virus (RSV) infection in an individual exposed to RSV, comprising:

a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-C, G-3' and wherein said kit does not comprises an RSV antigen or an immunostimulatory cytokine; and

instructions for administration of said composition to the respiratory tract of an individual to suppress an RSV infection.

Claim 12 (Original): The kit of claim 11, wherein the ISS comprises the sequence 5'-T, C, G-3'.

Claim 13 (Original): The kit of claim 11, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3' or 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3'.

Claim 14 (Original): The kit of claim 13, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTCC-3', 5'-AACGTTCG-3', 5'-GACGTTCC-3' and 5'-GACGTTCG-3'.

Claim 15 (Original): The kit of claim 11, wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTCGAGATGA-3' (SEQ ID NO:1).